Ticagrelor Therapy for RefrACTORy Migraine - Pilot Study
A study to reduce episodic and/or chronic migraine headache symptoms in patients who have a common heart defect called Patent Foramen Ovale
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAO4109
U.S. Govt. ID: NCT02518464
Contact: Robert Sommer: 212-342-0886 / rs2463@cumc.columbia.edu
Additional Study Information: This study is for patients who have severe migraine headaches that might be a result of a hole in the heart wall called a Patent Foreman Ovale, or PFO. It is known that as many as 40% of patients with migraine headaches also have a PFO. It is not well understood how the two are related, or how having a hole in the heart wall could cause headaches. In this study, we will test a drug, called ticagrelor (Brilanta), which is FDA approved for patients who have had heart attacks and are found to have blockages in their coronary arteries, but has never been tested as a treatment for migraines.
This study is closed
Investigator
Robert Sommer, MD
Do You Qualify?
Have you had migraines for at least one year? Yes No
Do you suffer at least 6 headache days per month? Yes No
Do you live in the New York metro area or are willing to travel for appointments? Yes No
Are you taking daily blood thinning medication? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Robert Sommer
rs2463@cumc.columbia.edu
212-342-0886